Terlipressin Acetate powder: How does the "pressure weapon" in the treatment of liver disease lead the new market trend?
Know Terlipressin Acetate powder
Terlipressin Acetate powder is a synthetic vasopressin analogue, which occupies an important position in the field of liver disease treatment because of its unique pharmacological characteristics and significant clinical value.
As an important vasoactive product, Terlipressin Acetate powder plays a key role in the medical field, especially in the complications related to liver disease. It is a synthetic vasopressin analog. Compared with traditional vasopressin, it has a longer half-life and better receptor selectivity, which makes it have significant advantages.
It is a white or off-white block or powder, which needs to be preserved under certain conditions (shading, no more than 20℃ in the shade). Terlipressin is mainly used to treat serious diseases such as esophageal variceal bleeding, hepatorenal syndrome and hepatogenic ascites. It is a first-line product recommended by international guidelines for type 1 hepatorenal syndrome (HRS-1) and has been included in the standard treatment process in many countries.
Characteristics and Mechanism of Terlipressin Acetate powder
1. Chemical characteristics and pharmacological advantages
The chemical structural formula of Terlipressin is Gly-Gly-Gly-Cys-Tyr-Phe-Gln-ASN-Cys-Pro-Lys-Gly-NH2, the molecular formula is C52H74N16O15S2, and the molecular weight is about 1227.37. This unique triglycosyl structure is the key to distinguish it from traditional vasopressin, and also determines its unique mechanism of action.
Its own activity is low, but it works by slowly releasing active substances through enzyme digestion in vivo. This characteristic makes Terlipressin Acetate powder have obvious clinical advantages: its triglyceride will be gradually cut off by tissue peptidase in vivo, and the active Lysine vasopressin will be released slowly. This "sustained release" mechanism enables terlipressin to maintain the contraction effect of smooth muscle for up to 10 hours, while ordinary vasopressin can only maintain its activity for 20-40 minutes.
2. Mechanism of action and receptor selectivity
As an agonist of vasopressin receptor, it has higher selectivity for V1 receptor than V2 receptor.
This receptor selectivity is the basis of its clinical safety and effectiveness. It works mainly through two ways:
Vasoconstriction: Terlipressin Acetate can obviously contract visceral vascular smooth muscle, reduce venous blood flow to hepatic portal vein system, thus reducing portal vein blood pressure, which has hemostatic effect on esophageal variceal bleeding.
Antidiuretic function: it can act on some receptors on the renal collecting duct and regulate water reabsorption. Although its antidiuretic activity is only 3% of that of natural vasopressin, Terlipressin Acetate still has certain anti-enuresis function.
Its main mechanism is to improve renal blood flow in patients with hepatorenal syndrome by reducing portal hypertension and portal vascular blood circulation, while increasing effective arterial volume and mean arterial pressure (MAP). Compared with de-DL -METANEPHRINE, it shows unique advantages, especially when Norepinephrine is invalid.
General situation of global market and regional differences
1.Global market structure
Terlipressin Acetate powder has shown a steady growth trend in the global market in recent years. This growth is mainly driven by many factors: the aging of the population, the rising incidence of liver disease and the continuous improvement of medical technology. On a global scale, many enterprises have occupied a dominant position in the market by virtue of their strong R&D strength and production capacity. North America, Europe and Asia are its main consumer markets, which are economically developed, densely populated and have a high level of medical care. It is worth noting that there are significant differences in its supervision on a global scale. However, it has been approved for use in many countries and has become the standard nursing therapy for HRS-1.
In 2022, it was approved by the FDA in the United States to improve the renal function of adults with hepatorenal syndrome and rapid decline in renal function. This approval makes it the first and only product approved for HRS-1 treatment in the United States, which is a milestone.
2.Regional market differences
Its market situation in different parts of the world is obviously different: North American market: Terlipressin Acetate was approved late in the American market, but it has great growth potential. American HRS-1 affects 30,000-40,000 patients every year. The Canadian market is similar, and it is mostly used in the research stage. European market: Europe is its traditional market, and it has been used in Europe for decades and has been the standard nursing therapy for HRS-1 patients. Asian market: Other markets in Asia are growing rapidly, especially in China. With the improvement of domestic medical level and the increase of the number of patients with liver disease, the demand for its production, research and development continues to grow. We and many manufacturers in China are increasing investment in R&D and constantly upgrading our technical level.
Industry Challenges and Technological Innovation
Technical challenges and solutions
Industry Terlipressin Acetate faces multiple technical challenges, mainly focusing on the following aspects:
Complexity of production process: As a kind of synthetic peptides, its production process is extremely complicated, and Terlipressin Acetate powder is necessary to accurately control the reaction conditions and purification process. The deviation of any link may affect the quality and potency of the final product. Strict quality control system is needed in the production process to ensure that each batch of products can meet the expected efficacy and safety standards.
Stability problem: it may face stability challenges during storage and use. The product should be stored in a shady and cool place. These requirements put forward higher requirements for transportation, storage and use.
In order to meet these challenges, we are actively promoting technological innovation, including: process optimization: constantly optimizing production processes, improving product purity and yield, and reducing production costs.
conclusion
As an important vasoactive product, it plays an irreplaceable role in liver cirrhosis and its complications. With the increase of the incidence of liver disease and the improvement of medical level, its market demand will continue to grow. In the future, with the deepening of research and technological progress, it is expected to show its value and provide more hope in more disease fields.
By strengthening R&D innovation, optimizing production technology and strictly controlling quality, Terlipressin Acetate industry will achieve healthy development and make greater contributions to human health.
Xi'an Faithful BioTech Co., Ltd. combines cutting-edge production technology with comprehensive quality assurance to provide high-quality Terlipressin Acetate powder that meets international pharmaceutical standards. Our commitment to excellent, competitive prices and technical support makes us the preferred partner of global healthcare providers and researchers. Please contact our technical team in sales11@faithfulbio.com to find out how our products can improve your formula.
This is a list of the names of the core scientific research documents that I referred to and relied on in the process of writing a soft article. These documents provide solid scientific evidence for the efficacy and mechanism mentioned in this paper.
《Practice guidance for the use of terlipressin for liver cirrhosis related complications (2021)》
《New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome》
《Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome》
《New England Journal of Medicine》（2021）
《Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study》
《Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study》
